| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25.
|
Nature
|
2008
|
16.10
|
|
2
|
Ceritinib in ALK-rearranged non-small-cell lung cancer.
|
N Engl J Med
|
2014
|
9.94
|
|
3
|
Probability of cancer in pulmonary nodules detected on first screening CT.
|
N Engl J Med
|
2013
|
4.64
|
|
4
|
Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.
|
N Engl J Med
|
2012
|
3.52
|
|
5
|
Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium.
|
J Natl Cancer Inst
|
2010
|
3.18
|
|
6
|
XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.
|
J Clin Oncol
|
2004
|
2.93
|
|
7
|
Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients.
|
J Clin Oncol
|
2007
|
2.52
|
|
8
|
Association between a 15q25 gene variant, smoking quantity and tobacco-related cancers among 17 000 individuals.
|
Int J Epidemiol
|
2009
|
1.97
|
|
9
|
VEGF polymorphisms and survival in early-stage non-small-cell lung cancer.
|
J Clin Oncol
|
2008
|
1.94
|
|
10
|
Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
|
Clin Cancer Res
|
2004
|
1.91
|
|
11
|
A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus.
|
Nat Genet
|
2013
|
1.67
|
|
12
|
Counterpoint: the myeloperoxidase -463G-->a polymorphism does not decrease lung cancer susceptibility in Caucasians.
|
Cancer Epidemiol Biomarkers Prev
|
2002
|
1.54
|
|
13
|
Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus.
|
Nat Genet
|
2012
|
1.52
|
|
14
|
Gene-environment interaction for the ERCC2 polymorphisms and cumulative cigarette smoking exposure in lung cancer.
|
Cancer Res
|
2002
|
1.45
|
|
15
|
Circulating 25-hydroxyvitamin D, VDR polymorphisms, and survival in advanced non-small-cell lung cancer.
|
J Clin Oncol
|
2008
|
1.42
|
|
16
|
Gene-smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer.
|
Cancer Epidemiol Biomarkers Prev
|
2005
|
1.38
|
|
17
|
Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients.
|
Clin Cancer Res
|
2005
|
1.36
|
|
18
|
Cannabis smoking and lung cancer risk: Pooled analysis in the International Lung Cancer Consortium.
|
Int J Cancer
|
2014
|
1.34
|
|
19
|
Genotypes and haplotypes of matrix metalloproteinase 1, 3 and 12 genes and the risk of lung cancer.
|
Carcinogenesis
|
2005
|
1.33
|
|
20
|
Polymorphisms in the DNA repair genes XRCC1 and ERCC2, smoking, and lung cancer risk.
|
Cancer Epidemiol Biomarkers Prev
|
2003
|
1.33
|
|
21
|
Combinations of the variant genotypes of GSTP1, GSTM1, and p53 are associated with an increased lung cancer risk.
|
Cancer Res
|
2002
|
1.33
|
|
22
|
Vitamin D is associated with improved survival in early-stage non-small cell lung cancer patients.
|
Cancer Epidemiol Biomarkers Prev
|
2005
|
1.33
|
|
23
|
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.
|
J Natl Cancer Inst
|
2010
|
1.30
|
|
24
|
Kernel machine SNP-set analysis for censored survival outcomes in genome-wide association studies.
|
Genet Epidemiol
|
2011
|
1.29
|
|
25
|
Previous lung diseases and lung cancer risk: a pooled analysis from the International Lung Cancer Consortium.
|
Am J Epidemiol
|
2012
|
1.27
|
|
26
|
A functional epidermal growth factor (EGF) polymorphism, EGF serum levels, and esophageal adenocarcinoma risk and outcome.
|
Clin Cancer Res
|
2008
|
1.27
|
|
27
|
Germline genetic contributions to risk for esophageal adenocarcinoma, Barrett's esophagus, and gastroesophageal reflux.
|
J Natl Cancer Inst
|
2013
|
1.25
|
|
28
|
Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer.
|
J Clin Oncol
|
2009
|
1.25
|
|
29
|
Polymorphisms of the NER pathway genes, ERCC1 and XPD are associated with esophageal adenocarcinoma risk.
|
Cancer Causes Control
|
2008
|
1.25
|
|
30
|
Vascular endothelial growth factor genotypes, haplotypes, gender, and the risk of non-small cell lung cancer.
|
Clin Cancer Res
|
2008
|
1.24
|
|
31
|
Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma.
|
J Clin Oncol
|
2010
|
1.23
|
|
32
|
Second hand smoke, age of exposure and lung cancer risk.
|
Lung Cancer
|
2008
|
1.19
|
|
33
|
Genetic variations in esophageal cancer risk and prognosis.
|
Gastroenterol Clin North Am
|
2009
|
1.15
|
|
34
|
Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung cancer.
|
Carcinogenesis
|
2008
|
1.15
|
|
35
|
MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancer.
|
J Clin Oncol
|
2007
|
1.12
|
|
36
|
A Large-scale genetic association study of esophageal adenocarcinoma risk.
|
Carcinogenesis
|
2010
|
1.12
|
|
37
|
Germline genetic variation, cancer outcome, and pharmacogenetics.
|
J Clin Oncol
|
2010
|
1.12
|
|
38
|
Smoking cessation before diagnosis and survival in early stage non-small cell lung cancer patients.
|
Lung Cancer
|
2006
|
1.11
|
|
39
|
Polymorphisms of vitamin D receptor and survival in early-stage non-small cell lung cancer patients.
|
Cancer Epidemiol Biomarkers Prev
|
2006
|
1.10
|
|
40
|
Modeling lung cancer risk in case-control studies using a new dose metric of smoking.
|
Cancer Epidemiol Biomarkers Prev
|
2005
|
1.09
|
|
41
|
Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes.
|
Pharmacogenet Genomics
|
2009
|
1.09
|
|
42
|
Genetic polymorphisms in N-acetyltransferase-2 and microsomal epoxide hydrolase, cumulative cigarette smoking, and lung cancer.
|
Cancer Epidemiol Biomarkers Prev
|
2002
|
1.06
|
|
43
|
Matrix metalloproteinase 1, 3 and 12 polymorphisms and esophageal adenocarcinoma risk and prognosis.
|
Carcinogenesis
|
2009
|
1.06
|
|
44
|
Predictors of severe acute and late toxicities in patients with localized head-and-neck cancer treated with radiation therapy.
|
Int J Radiat Oncol Biol Phys
|
2011
|
1.04
|
|
45
|
Genetic polymorphisms and head and neck cancer outcomes: a review.
|
Cancer Epidemiol Biomarkers Prev
|
2008
|
1.02
|
|
46
|
Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk.
|
Carcinogenesis
|
2008
|
1.01
|
|
47
|
Serum prognostic markers in head and neck cancer.
|
Clin Cancer Res
|
2010
|
1.01
|
|
48
|
Risk of pancreatic cancer among individuals with a family history of cancer of the pancreas.
|
Int J Cancer
|
2002
|
1.01
|
|
49
|
MDM2 promoter polymorphism and pancreatic cancer risk and prognosis.
|
Clin Cancer Res
|
2008
|
1.01
|
|
50
|
Genetic polymorphisms as predictive and prognostic biomarkers in gynecological cancers: a systematic review.
|
Gynecol Oncol
|
2011
|
1.00
|
|
51
|
Comparison of pathway analysis approaches using lung cancer GWAS data sets.
|
PLoS One
|
2012
|
1.00
|
|
52
|
Myeloperoxidase and superoxide dismutase polymorphisms are associated with an increased risk of developing pancreatic adenocarcinoma.
|
Cancer
|
2008
|
0.99
|
|
53
|
Dietary iron, zinc, and calcium and the risk of lung cancer.
|
Epidemiology
|
2005
|
0.98
|
|
54
|
Impact and feasibility of a comprehensive geriatric assessment in the oncology setting: a pilot study.
|
Am J Clin Oncol
|
2012
|
0.98
|
|
55
|
Treatment of the elderly when cure is the goal: the influence of age on treatment selection and efficacy for stage III non-small cell lung cancer.
|
J Thorac Oncol
|
2011
|
0.98
|
|
56
|
Vascular endothelial growth factor polymorphisms and esophageal cancer prognosis.
|
Clin Cancer Res
|
2009
|
0.97
|
|
57
|
Prognostic factors for cure, recurrence and long-term survival after surgical resection of thymoma.
|
J Thorac Oncol
|
2014
|
0.96
|
|
58
|
Association between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in Caucasians.
|
PLoS One
|
2013
|
0.96
|
|
59
|
p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis.
|
Clin Cancer Res
|
2009
|
0.96
|
|
60
|
p53 Arg72Pro polymorphism, HPV status and initiation, progression, and development of cervical cancer: a systematic review and meta-analysis.
|
Clin Cancer Res
|
2012
|
0.95
|
|
61
|
Matrix metalloproteinase-1 promoter polymorphism and lung cancer risk.
|
Cancer Epidemiol Biomarkers Prev
|
2005
|
0.94
|
|
62
|
Cancer patients acceptance, understanding, and willingness-to-pay for pharmacogenomic testing.
|
Pharmacogenet Genomics
|
2014
|
0.93
|
|
63
|
Interactions among genetic variants in apoptosis pathway genes, reflux symptoms, body mass index, and smoking indicate two distinct etiologic patterns of esophageal adenocarcinoma.
|
J Clin Oncol
|
2010
|
0.92
|
|
64
|
Lack of correlation between a self-administered subjective GERD questionnaire and pathologic GERD diagnosed by 24-h esophageal pH monitoring.
|
J Gastrointest Surg
|
2010
|
0.92
|
|
65
|
Dietary vitamin D intake and serum 25-hydroxyvitamin D level in relation to disease outcomes in head and neck cancer patients.
|
Int J Cancer
|
2010
|
0.92
|
|
66
|
Comorbidity and prognosis in head and neck cancers: Differences by subsite, stage, and human papillomavirus status.
|
Head Neck
|
2013
|
0.91
|
|
67
|
Genetic variations as cancer prognostic markers: review and update.
|
Hum Mutat
|
2009
|
0.91
|
|
68
|
Primary tumor xenografts of human lung adeno and squamous cell carcinoma express distinct proteomic signatures.
|
J Proteome Res
|
2010
|
0.91
|
|
69
|
Vascular endothelial growth factor pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: a systematic review and meta-analysis.
|
Clin Cancer Res
|
2012
|
0.90
|
|
70
|
Associated Links Among Smoking, Chronic Obstructive Pulmonary Disease, and Small Cell Lung Cancer: A Pooled Analysis in the International Lung Cancer Consortium.
|
EBioMedicine
|
2015
|
0.90
|
|
71
|
Matrix metalloproteinase polymorphisms and survival in stage I non-small cell lung cancer.
|
Clin Cancer Res
|
2006
|
0.89
|
|
72
|
No association between the p21 codon 31 serine-arginine polymorphism and lung cancer risk.
|
Cancer Epidemiol Biomarkers Prev
|
2003
|
0.89
|
|
73
|
Pharmacogenetic and germline prognostic markers of lung cancer.
|
J Thorac Oncol
|
2011
|
0.89
|
|
74
|
P53 (codon 72) and P21 (codon 31) polymorphisms alter in vivo mRNA expression of p21.
|
Lung Cancer
|
2003
|
0.89
|
|
75
|
The changing incidence of human papillomavirus-associated oropharyngeal cancer using multiple imputation from 2000 to 2010 at a Comprehensive Cancer Centre.
|
Cancer Epidemiol
|
2013
|
0.88
|
|
76
|
Genome-wide DNA methylation profiling of cell-free serum DNA in esophageal adenocarcinoma and Barrett esophagus.
|
Neoplasia
|
2012
|
0.88
|
|
77
|
Association of the 15q25 and 5p15 lung cancer susceptibility regions with gene expression in lung tumor tissue.
|
Cancer Epidemiol Biomarkers Prev
|
2012
|
0.86
|
|
78
|
Primary esophageal and gastro-esophageal junction cancer xenograft models: clinicopathological features and engraftment.
|
Lab Invest
|
2013
|
0.85
|
|
79
|
A rapid outcomes ascertainment system improves the quality of prognostic and pharmacogenetic outcomes from observational studies.
|
Cancer Epidemiol Biomarkers Prev
|
2008
|
0.85
|
|
80
|
Second-hand smoke as a predictor of smoking cessation among lung cancer survivors.
|
J Clin Oncol
|
2014
|
0.85
|
|
81
|
Social environment, secondary smoking exposure, and smoking cessation among head and neck cancer patients.
|
Cancer
|
2013
|
0.84
|
|
82
|
Validation of genetic sequence variants as prognostic factors in early-stage head and neck squamous cell cancer survival.
|
Clin Cancer Res
|
2011
|
0.84
|
|
83
|
Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group.
|
BMC Cancer
|
2011
|
0.84
|
|
84
|
Association between polymorphisms in cancer-related genes and early onset of esophageal adenocarcinoma.
|
Neoplasia
|
2011
|
0.84
|
|
85
|
Genetic sequence variants and the development of secondary primary cancers in patients with head and neck cancers.
|
Cancer
|
2011
|
0.83
|
|
86
|
Genetic polymorphisms of MnSOD, GSTM1, GSTT1, and OGG1 in coal workers' pneumoconiosis.
|
J Occup Environ Med
|
2002
|
0.83
|
|
87
|
Special considerations in prognostic research in cancer involving genetic polymorphisms.
|
BMC Med
|
2013
|
0.83
|
|
88
|
Genetic polymorphisms of DNA repair genes and chromosomal damage in workers exposed to 1,3-butadiene.
|
Carcinogenesis
|
2010
|
0.83
|
|
89
|
Interactions between genetic polymorphisms in the apoptotic pathway and environmental factors on esophageal adenocarcinoma risk.
|
Carcinogenesis
|
2011
|
0.82
|
|
90
|
Validation of a one-page patient-reported Charlson comorbidity index questionnaire for upper aerodigestive tract cancer patients.
|
Oral Oncol
|
2013
|
0.82
|
|
91
|
An association between glutathione S-transferase P1 gene polymorphism and younger age at onset of lung carcinoma.
|
Cancer
|
2006
|
0.82
|
|
92
|
Interactions between environmental factors and polymorphisms in angiogenesis pathway genes in esophageal adenocarcinoma risk: a case-only study.
|
Cancer
|
2011
|
0.82
|
|
93
|
A comprehensive catalogue of functional genetic variations in the EGFR pathway: protein-protein interaction analysis reveals novel genes and polymorphisms important for cancer research.
|
Int J Cancer
|
2009
|
0.82
|
|
94
|
Addition of multiple rare SNPs to known common variants improves the association between disease and gene in the Genetic Analysis Workshop 17 data.
|
BMC Proc
|
2011
|
0.82
|
|
95
|
Genetic sequence variants in vitamin D metabolism pathway genes, serum vitamin D level and outcome in head and neck cancer patients.
|
Int J Cancer
|
2012
|
0.81
|
|
96
|
Second hand smoke exposure and survival in early-stage non-small-cell lung cancer patients.
|
Clin Cancer Res
|
2006
|
0.81
|
|
97
|
Resource utilization and costs during the initial years of lung cancer screening with computed tomography in Canada.
|
J Thorac Oncol
|
2014
|
0.81
|
|
98
|
Association of two BRM promoter polymorphisms with head and neck squamous cell carcinoma risk.
|
Carcinogenesis
|
2013
|
0.81
|
|
99
|
Single nucleotide polymorphisms in the matrix metalloproteinase gene family and the frequency and duration of gastroesophageal reflux disease influence the risk of esophageal adenocarcinoma.
|
Int J Cancer
|
2012
|
0.81
|
|
100
|
Epidermal growth factor A61G gene polymorphism, gastroesophageal reflux disease and esophageal adenocarcinoma risk.
|
Carcinogenesis
|
2009
|
0.81
|
|
101
|
Genetic associations with sporadic neuroendocrine tumor risk.
|
Carcinogenesis
|
2011
|
0.81
|
|
102
|
Pharmacokinetics and pharmacogenomics in breast cancer chemotherapy.
|
Adv Drug Deliv Rev
|
2008
|
0.80
|
|
103
|
A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer.
|
Cancer Chemother Pharmacol
|
2012
|
0.80
|
|
104
|
A pathway-based association analysis model using common and rare variants.
|
BMC Proc
|
2011
|
0.79
|
|
105
|
Two BRM promoter insertion polymorphisms increase the risk of early-stage upper aerodigestive tract cancers.
|
Cancer Med
|
2014
|
0.79
|
|
106
|
Association of MDM2 T309G and p53 Arg72Pro polymorphisms and gastroesophageal reflux disease with survival in esophageal adenocarcinoma.
|
J Gastroenterol Hepatol
|
2013
|
0.78
|
|
107
|
Point-of-care outcome assessment in the cancer clinic: audit of data quality.
|
Radiother Oncol
|
2010
|
0.78
|
|
108
|
Factors influencing a specific pathologic diagnosis of non-small-cell lung carcinoma.
|
Clin Lung Cancer
|
2013
|
0.77
|
|
109
|
Serum proteomic classifier for predicting response to epidermal growth factor receptor inhibitor therapy: have we built a better mousetrap?
|
J Natl Cancer Inst
|
2007
|
0.77
|
|
110
|
Clinical Practice Recommendations for the Management and Prevention of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers.
|
Ther Drug Monit
|
2016
|
0.77
|
|
111
|
Studying genetic variations in cancer prognosis (and risk): a primer for clinicians.
|
Oncologist
|
2009
|
0.76
|
|
112
|
Interaction of polymorphisms in mitotic regulator genes with cigarette smoking and pancreatic cancer risk.
|
Mol Carcinog
|
2013
|
0.76
|
|
113
|
VEGF pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: a 2013 update.
|
Pharmacogenomics
|
2013
|
0.76
|
|
114
|
Algorithms for systematic identification of small subgraphs.
|
Methods Mol Biol
|
2012
|
0.75
|
|
115
|
Corrigendum: Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer.
|
Nat Genet
|
2017
|
0.75
|
|
116
|
Informed genome-wide association analysis with family history as a secondary phenotype identifies novel loci of lung cancer.
|
Genet Epidemiol
|
2015
|
0.75
|
|
117
|
Should oncologists measure the mRNA and protein expression levels of ERCC1 and RRM1 in non-small-cell lung cancer?
|
Nat Clin Pract Oncol
|
2007
|
0.75
|
|
118
|
Can routine collection of patient reported outcome data actually improve person-centered health?
|
Healthc Pap
|
2011
|
0.75
|
|
119
|
Correction: Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
|
PLoS One
|
2015
|
0.75
|
|
120
|
Two words.
|
Conn Med
|
2014
|
0.75
|
|
121
|
The association of family history of cancer and medical history with pancreatic cancer risk.
|
Pancreas
|
2014
|
0.75
|